It is noteworthy that eribulin was the most effective MTA in our panel at inhibiting p130Cas-Src signaling, a pathway implicated in EMT, since eribulin provides a survival advantage in breast cancer patients, including those with metastatic disease, which is often characterized by EMT [63]. Here, SRC is linked to breast carcinoma.